16:04 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Renal cancer In vitro and cell culture studies identified an aminothiazole-based negative allosteric modulator (NAM) of CSNK2 that could help treat renal cell carcinoma (RCC). Chemical synthesis and in vitro testing of aminothiazole analogs...
21:00 , Aug 17, 2017 |  BC Innovations  |  Translation in Brief

Stopping the invasion

A team from the Netherlands Cancer Institute (NKI) has identified a network of extracellular matrix proteins that drives glioblastoma invasiveness and a master switch -- interferon regulatory factor 3 (IRF3) -- that can turn it...
17:44 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture studies suggest activating IRF3 or inhibiting its negative regulator CSNK2 could help treat glioblastoma multiforme (GBM). In mouse brain slices co-cultured with a patient-derived GBM cell line, vector-mediated constitutively active...
23:53 , Feb 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Huntington's disease (HD) Patient sample and mouse studies suggest inhibiting CSNK2A2 could help treat HD. Levels of CSNK2A2 were higher in striatal tissue samples from HD patients and striatal and gastrocnemius muscle tissue samples...
01:29 , Dec 14, 2013 |  BC Extra  |  Financial News

Senhwa raises $17 million in series B

Cancer company Senhwa Biosciences Inc. (New Taipei City, Taiwan) raised $17 million in a series B round from existing and new investors including H&Q Asia Pacific; Morningside; and China Investment & Development. Senhwa's CX-5461 ,...
07:00 , Apr 23, 2012 |  BC Week In Review  |  Clinical News

Cylene Pharmaceuticals preclinical data

In a mouse xenograft model of cancer, CX-8184 showed "potent" antitumor activity and was well tolerated. Additionally, the second-generation oral protein kinase CK2 inhibitor demonstrated broad anti-proliferative activity against a panel of 32 cancer cell...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Clinical News

CX-4945: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 27 patients showed that oral CX-4945 produced 6 cases of stable disease. The MTD was twice-daily 1,000 mg CX-4945 given for the first 3 consecutive weeks of...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Clinical News

CX-4945: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 17 patients showed that oral CX-4945 produced 3 cases of stable disease. The MTD was 600 mg CX-4945 given 4 times daily for the first 3 consecutive...
07:00 , Oct 25, 2010 |  BC Week In Review  |  Company News

Cylene Pharmaceuticals, Horizon Discovery Ltd. deal

Cylene will use Horizon's X-MAN panel of over 250 genetically-defined human cancer cell lines to identify patients who will respond best to Cylene's oral protein kinase CK2 inhibitor, CX-4945 , in an upcoming Phase II...
07:00 , Sep 27, 2010 |  BC Week In Review  |  Clinical News

CX-4945: Phase I started

Cylene began an open-label, dose-escalation, U.S. Phase I trial to evaluate oral CX-4945 given 4 times daily for the first 21 days of a 28-day cycle in 20 patients with relapsed or refractory MM. Cylene...